| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
|
N Engl J Med
|
2003
|
8.93
|
|
2
|
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
|
J Clin Oncol
|
2013
|
3.75
|
|
3
|
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma.
|
Blood
|
2006
|
2.43
|
|
4
|
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.
|
Blood
|
2007
|
2.38
|
|
5
|
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.
|
Blood
|
2012
|
2.38
|
|
6
|
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.
|
Blood
|
2010
|
2.25
|
|
7
|
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.
|
Blood
|
2003
|
2.23
|
|
8
|
Optimizing protein stability in vivo.
|
Mol Cell
|
2009
|
2.15
|
|
9
|
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.
|
Blood
|
2002
|
1.95
|
|
10
|
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.
|
Blood
|
2007
|
1.93
|
|
11
|
The impact of extramedullary disease at presentation on the outcome of myeloma.
|
Leuk Lymphoma
|
2009
|
1.77
|
|
12
|
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
|
J Clin Oncol
|
2011
|
1.71
|
|
13
|
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
|
Cancer Res
|
2007
|
1.70
|
|
14
|
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.
|
Blood
|
2010
|
1.67
|
|
15
|
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
|
J Clin Oncol
|
2011
|
1.66
|
|
16
|
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response.
|
EMBO J
|
2011
|
1.65
|
|
17
|
Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma.
|
Haematologica
|
2006
|
1.64
|
|
18
|
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
|
Radiology
|
2014
|
1.64
|
|
19
|
The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma.
|
Clin Cancer Res
|
2011
|
1.61
|
|
20
|
Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity.
|
Blood
|
2003
|
1.60
|
|
21
|
High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma.
|
Leuk Lymphoma
|
2010
|
1.58
|
|
22
|
Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia.
|
Cancer Res
|
2003
|
1.53
|
|
23
|
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
|
Blood
|
2002
|
1.51
|
|
24
|
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis.
|
Leuk Lymphoma
|
2006
|
1.49
|
|
25
|
Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns.
|
Br J Haematol
|
2009
|
1.48
|
|
26
|
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
|
Blood
|
2008
|
1.45
|
|
27
|
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
|
Clin Cancer Res
|
2011
|
1.44
|
|
28
|
Self-expanding stent implantation in arterial duct during hybrid palliation of hypoplastic left heart syndrome: midterm experience with a specially designed stent.
|
EuroIntervention
|
2015
|
1.39
|
|
29
|
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.
|
Clin Cancer Res
|
2010
|
1.39
|
|
30
|
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.
|
Blood
|
2010
|
1.36
|
|
31
|
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.
|
Blood
|
2013
|
1.35
|
|
32
|
Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia.
|
Blood
|
2002
|
1.34
|
|
33
|
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.
|
Blood
|
2012
|
1.33
|
|
34
|
Untangling the unfolded protein response.
|
Cell Cycle
|
2008
|
1.32
|
|
35
|
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
|
Blood
|
2002
|
1.22
|
|
36
|
Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma.
|
Ther Clin Risk Manag
|
2006
|
1.20
|
|
37
|
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.
|
Haematologica
|
2008
|
1.20
|
|
38
|
Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
|
Clin Cancer Res
|
2008
|
1.19
|
|
39
|
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.
|
J Biol Chem
|
2002
|
1.18
|
|
40
|
The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
|
Clin Cancer Res
|
2003
|
1.17
|
|
41
|
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells.
|
Blood
|
2013
|
1.16
|
|
42
|
Epigenetic consequences of AML1-ETO action at the human c-FMS locus.
|
EMBO J
|
2003
|
1.14
|
|
43
|
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma.
|
Blood
|
2007
|
1.11
|
|
44
|
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.
|
Blood
|
2004
|
1.09
|
|
45
|
Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma.
|
Br J Haematol
|
2002
|
1.09
|
|
46
|
Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma.
|
Cancer Lett
|
2006
|
1.07
|
|
47
|
Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.06
|
|
48
|
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.
|
Blood
|
2003
|
1.05
|
|
49
|
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
|
Br J Haematol
|
2014
|
1.04
|
|
50
|
The role of second autografts in the management of myeloma at first relapse.
|
Haematologica
|
2006
|
1.03
|
|
51
|
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
|
Genes Chromosomes Cancer
|
2011
|
1.02
|
|
52
|
An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents.
|
Clin Cancer Res
|
2003
|
1.02
|
|
53
|
Tobacco and alcohol consumption and the risk of non-Hodgkin lymphoma.
|
Cancer Causes Control
|
2004
|
1.01
|
|
54
|
A modified method for whole exome resequencing from minimal amounts of starting DNA.
|
PLoS One
|
2012
|
1.00
|
|
55
|
The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
|
Haematologica
|
2007
|
1.00
|
|
56
|
Aminopeptidase inhibition as a targeted treatment strategy in myeloma.
|
Mol Cancer Ther
|
2009
|
0.99
|
|
57
|
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.
|
Haematologica
|
2010
|
0.98
|
|
58
|
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
|
Lancet Oncol
|
2003
|
0.98
|
|
59
|
Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7.
|
Genes Chromosomes Cancer
|
2002
|
0.97
|
|
60
|
Remote diagnosis of congenital heart disease: the impact of telemedicine.
|
Arch Dis Child
|
2009
|
0.97
|
|
61
|
Differential transcription factor occupancy but evolutionarily conserved chromatin features at the human and mouse M-CSF (CSF-1) receptor loci.
|
Nucleic Acids Res
|
2003
|
0.97
|
|
62
|
A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
|
Clin Cancer Res
|
2004
|
0.97
|
|
63
|
Gender disparities in the tumor genetics and clinical outcome of multiple myeloma.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.97
|
|
64
|
Non-Hodgkin lymphoma secondary to cancer chemotherapy.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.97
|
|
65
|
DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma.
|
Carcinogenesis
|
2004
|
0.96
|
|
66
|
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses.
|
Blood
|
2004
|
0.96
|
|
67
|
A molecular study of the t(4;14) in multiple myeloma.
|
Br J Haematol
|
2002
|
0.95
|
|
68
|
Improved risk stratification in myeloma using a microRNA-based classifier.
|
Br J Haematol
|
2013
|
0.95
|
|
69
|
High-throughput association testing on DNA pools to identify genetic variants that confer susceptibility to acute myeloid leukemia.
|
Cancer Epidemiol Biomarkers Prev
|
2004
|
0.95
|
|
70
|
Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.
|
Blood
|
2014
|
0.94
|
|
71
|
Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.
|
Leuk Lymphoma
|
2008
|
0.93
|
|
72
|
Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress.
|
Cancer Lett
|
2013
|
0.93
|
|
73
|
A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment.
|
Clin Cancer Res
|
2011
|
0.93
|
|
74
|
t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma.
|
Genes Chromosomes Cancer
|
2006
|
0.92
|
|
75
|
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
|
Br J Haematol
|
2007
|
0.92
|
|
76
|
Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.
|
PLoS One
|
2013
|
0.91
|
|
77
|
Association between non-Hodgkin lymphoma and haplotypes in the TNF region.
|
Br J Haematol
|
2006
|
0.91
|
|
78
|
Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma.
|
Br J Haematol
|
2011
|
0.91
|
|
79
|
Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry.
|
Biol Blood Marrow Transplant
|
2011
|
0.91
|
|
80
|
Minimal residual disease monitoring in multiple myeloma.
|
Best Pract Res Clin Haematol
|
2002
|
0.91
|
|
81
|
High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD.
|
Clin Transplant
|
2012
|
0.89
|
|
82
|
The detection of t(14;18) in archival lymph nodes: development of a fluorescence in situ hybridization (FISH)-based method and evaluation by comparison with polymerase chain reaction.
|
J Mol Diagn
|
2003
|
0.89
|
|
83
|
Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease.
|
PLoS One
|
2013
|
0.89
|
|
84
|
Causal models of leukaemia and lymphoma.
|
IARC Sci Publ
|
2004
|
0.89
|
|
85
|
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
|
Br J Haematol
|
2010
|
0.89
|
|
86
|
Association of metabolic gene polymorphisms with tobacco consumption in healthy controls.
|
Int J Cancer
|
2004
|
0.89
|
|
87
|
Conformational properties of the unfolded state of Im7 in nondenaturing conditions.
|
J Mol Biol
|
2011
|
0.89
|
|
88
|
Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma.
|
Br J Haematol
|
2005
|
0.88
|
|
89
|
Atrial septal defect closure with an Amplatzer septal occluder fenestrated with a coronary stent in a child with pulmonary arterial hypertension.
|
Cardiol Young
|
2012
|
0.87
|
|
90
|
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.
|
Genes Chromosomes Cancer
|
2014
|
0.87
|
|
91
|
Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma.
|
Clin Lymphoma Myeloma
|
2006
|
0.87
|
|
92
|
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.
|
Haematologica
|
2011
|
0.87
|
|
93
|
Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
|
Br J Haematol
|
2005
|
0.87
|
|
94
|
Home support for children with complex congenital heart disease using videoconferencing via broadband: initial results.
|
J Telemed Telecare
|
2008
|
0.85
|
|
95
|
New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survival.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
0.84
|
|
96
|
Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.
|
Clin Cancer Res
|
2013
|
0.84
|
|
97
|
RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukaemia.
|
Leuk Res
|
2006
|
0.83
|
|
98
|
Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities.
|
Br J Haematol
|
2002
|
0.83
|
|
99
|
CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication.
|
Blood
|
2002
|
0.82
|
|
100
|
Streptolysin-O reversible permeabilisation is an effective method to transfect siRNAs into myeloma cells.
|
J Immunol Methods
|
2008
|
0.82
|
|
101
|
Application of DNA pooling to large studies of disease.
|
Stat Med
|
2004
|
0.82
|
|
102
|
A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma.
|
Br J Haematol
|
2010
|
0.82
|
|
103
|
Proteasome inhibition and multiple myeloma.
|
Curr Opin Investig Drugs
|
2007
|
0.81
|
|
104
|
Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma.
|
J Clin Oncol
|
2010
|
0.81
|
|
105
|
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.
|
Leuk Lymphoma
|
2013
|
0.81
|
|
106
|
Neuron-specific enolase expression in multiple myeloma.
|
Lancet Oncol
|
2006
|
0.80
|
|
107
|
An update on drug combinations for treatment of myeloma.
|
Expert Opin Investig Drugs
|
2008
|
0.80
|
|
108
|
Translocation t(11;14) in multiple myeloma: Analysis of translocation breakpoints on der(11) and der(14) chromosomes suggests complex molecular mechanisms of recombination.
|
Genes Chromosomes Cancer
|
2004
|
0.80
|
|
109
|
Identification of autophosphorylation inhibitors of the inositol-requiring enzyme 1 alpha (IRE1α) by high-throughput screening using a DELFIA assay.
|
J Biomol Screen
|
2012
|
0.80
|
|
110
|
Diagnosis of congenital heart disease in neonates by videoconferencing: an eight-year experience.
|
J Telemed Telecare
|
2008
|
0.80
|
|
111
|
Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma.
|
Br J Haematol
|
2010
|
0.79
|
|
112
|
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
|
Haematologica
|
2006
|
0.79
|
|
113
|
Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
|
Eur J Haematol
|
2008
|
0.79
|
|
114
|
Enhancing cancer clonality analysis with integrative genomics.
|
BMC Bioinformatics
|
2015
|
0.79
|
|
115
|
Haplotypic variation in MRE11, RAD50 and NBS1 and risk of non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2006
|
0.79
|
|
116
|
UK multicenter experience using the Gore septal occluder (GSO(TM) ) for atrial septal defect closure in children and adults.
|
Catheter Cardiovasc Interv
|
2013
|
0.78
|
|
117
|
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism.
|
Oncogene
|
2003
|
0.78
|
|
118
|
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
|
Hematology Am Soc Hematol Educ Program
|
2012
|
0.78
|
|
119
|
Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation.
|
Leuk Lymphoma
|
2008
|
0.78
|
|
120
|
Current and potential epigenetic targets in multiple myeloma.
|
Epigenomics
|
2014
|
0.78
|
|
121
|
Poor metabolizer status at the cytochrome P450 2C9 and 2D6 loci does not modulate susceptibility to therapy-related acute myeloid leukaemia.
|
Br J Haematol
|
2003
|
0.77
|
|
122
|
Understanding the molecular biology of myeloma and its therapeutic implications.
|
Expert Rev Hematol
|
2012
|
0.77
|
|
123
|
Early clinical experience with a modified Amplatzer ductal occluder for transcatheter arterial duct occlusion in infants and small children.
|
Catheter Cardiovasc Interv
|
2013
|
0.77
|
|
124
|
Could DNA methylation become a useful measure for multiple myeloma prognoses?
|
Expert Rev Hematol
|
2011
|
0.77
|
|
125
|
Identification of a novel t(7;14) translocation in multiple myeloma resulting in overexpression of EGFR.
|
Genes Chromosomes Cancer
|
2013
|
0.77
|
|
126
|
Transfection of siRNAs in multiple myeloma cell lines.
|
Methods Mol Biol
|
2010
|
0.77
|
|
127
|
The impact of response on bone-directed therapy in patients with multiple myeloma.
|
Blood
|
2013
|
0.77
|
|
128
|
Novel drugs in myeloma: harnessing tumour biology to treat myeloma.
|
Recent Results Cancer Res
|
2011
|
0.77
|
|
129
|
The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma.
|
Expert Rev Hematol
|
2014
|
0.77
|
|
130
|
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
|
Br J Haematol
|
2014
|
0.76
|
|
131
|
Mapping local structural perturbations in the native state of stefin B (cystatin B) under amyloid forming conditions.
|
Front Mol Neurosci
|
2012
|
0.76
|
|
132
|
The current landscape of multiple myeloma treatment.
|
Leuk Res
|
2008
|
0.76
|
|
133
|
Understanding the multiple biological aspects leading to myeloma.
|
Haematologica
|
2014
|
0.76
|
|
134
|
The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells.
|
Blood
|
2005
|
0.76
|
|
135
|
A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
136
|
An early computed tomography-guided antifungal treatment strategy is safe and efficacious in patients undergoing chemotherapy for high-risk acute leukemia.
|
Leuk Lymphoma
|
2011
|
0.75
|
|
137
|
Further analyses of the Myeloma IX Study.
|
Lancet
|
2011
|
0.75
|
|
138
|
Reply to M. Roschewski et al.
|
J Clin Oncol
|
2014
|
0.75
|
|
139
|
Staged interventional and surgical management for complex low birthweight tetralogy of Fallot: another imperfect but legitimate strategy.
|
BMJ Case Rep
|
2013
|
0.75
|
|
140
|
IVIG, aspirin, and Kawasaki disease.
|
J Pediatr
|
2003
|
0.75
|
|
141
|
Targeting bone as a therapy for myeloma.
|
Cancer Microenviron
|
2011
|
0.75
|
|
142
|
Initial experience with live three-dimensional image overlay for ductal stenting in hypoplastic left heart syndrome.
|
EuroIntervention
|
2016
|
0.75
|
|
143
|
Early experience with the Occlutech PLD occluder for mitral paravalvar leak closure through a hybrid transapical approach.
|
EuroIntervention
|
2016
|
0.75
|
|
144
|
A comparison of ISDN and home broadband transmission in delivering home support for infants with major congenital heart disease.
|
J Telemed Telecare
|
2013
|
0.75
|
|
145
|
First report of fatal human infections with the cactophilic yeast Sporopachydermia cereana.
|
J Infect
|
2011
|
0.75
|
|
146
|
Utilizing new biology to guide treatment directions in myeloma.
|
Clin Adv Hematol Oncol
|
2013
|
0.75
|
|
147
|
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.
|
Br J Haematol
|
2013
|
0.75
|
|
148
|
Early European experience with the Venus P-valve®: filling the gap in percutaneous pulmonary valve implantation.
|
EuroIntervention
|
2016
|
0.75
|
|
149
|
The t(12:21) is underrepresented in childhood B-lineage acute lymphoblastic leukemia in Kerala, Southern India.
|
Haematologica
|
2005
|
0.75
|
|
150
|
Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
|
J Med Econ
|
2012
|
0.75
|
|
151
|
Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis.
|
Hematology
|
2011
|
0.75
|
|
152
|
Long distance vectorette PCR (LDV PCR).
|
Methods Mol Biol
|
2002
|
0.75
|
|
153
|
Severe left main coronary artery stenosis with abnormal branching pattern in a patient with mild supravalvar aortic stenosis and Williams-Beuren syndrome.
|
Congenit Heart Dis
|
2013
|
0.75
|
|
154
|
Initial experience of pacing with a lumenless lead system in patients with congenital heart disease.
|
Pacing Clin Electrophysiol
|
2009
|
0.75
|
|
155
|
The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
|
Leuk Lymphoma
|
2014
|
0.75
|